Management ChangeJun 5, 2026, 04:13 PM
Grace Therapeutics VP of Clinical Operations Carrie D Andrea Departs
AI Summary
Grace Therapeutics, Inc. announced that Carrie D Andrea ceased serving as Vice President of Clinical Operations, with her employment ending on June 5, 2026. Ms. D Andrea is expected to execute a separation agreement entitling her to severance benefits consistent with a prior Letter Agreement. Concurrently, she entered into a twelve-month Consulting Agreement with the Company, effective June 5, 2026, to provide services at a rate of $250 per hour. During the consulting term, her stock option awards will continue to vest, and she will have 90 days after the Consulting Agreement's termination to exercise vested options.
Key Highlights
- Carrie D Andrea ceased serving as Vice President of Clinical Operations, effective June 5, 2026.
- Ms. D Andrea is expected to execute a separation agreement for severance benefits.
- She entered into a 12-month Consulting Agreement with the Company on June 5, 2026.
- Under the Consulting Agreement, she will provide services for a fee of $250 per hour.
- Stock option awards will continue to vest during the term of the Consulting Agreement.
- Ms. D Andrea will have 90 days post-consulting termination to exercise any vested stock options.
Price Impact
More from GRCE